all report title image
  • Published On : Oct 2022
  • Code : CMI5272
  • Industry : Biotechnology
  • Pages : 170
  • Formats :

The global protein engineering market was valued at US$ 1,936.7 Mn in 2021 and is forecast to reach a value of US$ 5,355.8 Mn by 2028 at a CAGR of 15.6% between 2022 and 2028. The global protein engineering market is experiencing strong growth due to the rising government funding for protein engineering. Furthermore, increase in adoption of protein drugs over non-protein drugs and increase in prevalence of protein deficient diseases is expected to boost the growth of the market. However, factors such as High production costs of therapeutic proteins and dearth of skilled professionals are expected to hamper growth of the market.

Global Protein Engineering Market: Regional Insights

Based on geography, the global protein engineering market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period due to the rising incidence of chronic diseases and increasing adoption of protein drugs over non-protein drugs. The increasing prevalence of chronic diseases, such as cancer and other autoimmune diseases has significantly increased the use of monoclonal bodies for the treatment of diseases. American Cancer Society, in 2022, over 1.9 million new cancer cases and 609,360 deaths from cancer are expected to occur in the U.S., which is about 1,670 deaths a day.

Asia Pacific is also expected to witness robust growth in the global protein engineering market owing to increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases, and upsurge in research and development activities. For instance, in June 2021, Indian Institute of Science Education and Research (IISER) Bhopal invented a new technology that can deliver active molecules to specific protein sections. It will help cancer patients with precise imaging-guided tumour surgeries and directed cancer chemotherapeutics in the coming years.

Figure 1. Global Protein Engineering Market Share (%), by Region, 2021

Protein Engineering  | Coherent Market Insights

Global Protein Engineering Market Drivers:

Increase in adoption of protein drugs over non-protein drugs worldwide is expected to propel growth of the global protein engineering market over the forecast period. Therapeutic proteins are widely used to treat cancer, HIV, and other diseases. Monoclonal antibodies, cytokines, and IFNs are some examples of the macromolecular therapeutic proteins. Protein and peptide-based drugs have potential applications as therapeutic agents since they have higher efficacy and lower toxicity than chemical drugs. Around 60 US FDA approved peptide drugs are in the markets and this number is expected to grow during the forecast period.

Increase in prevalence of protein deficient diseases across the globe is expected to augment the growth of the global protein engineering market over the forecast period. For instance, protein is an important part of a basic diet, but an estimated one billion people around the world suffer from protein deficiency. The National Institutes of Health (NIH) estimates a 12.2% current risk of protein deficiency globally. Moreover, NIH predict that globally, 15.1% or 1.4 billion people will be at risk of protein deficiency by 2050 because of demographic changes.

Global Protein Engineering Market Opportunities:

Growing focus on protein-based drug development is expected to provide significant growth opportunities for players operating in the protein engineering market. For instance, in January 2022, Amgen and Generate Biomedicines teamed up to discover and create protein therapeutics for five targets across several therapeutic areas and multiple modalities, through a collaboration that could generate US$ 1.9 billion for the Flagship Pioneering spinout, to facilitate testing and learning which proteins work best against which disease targets.

Government funding for protein engineering and favorable government initiatives is expected to offer lucrative growth opportunities for players in the global protein engineering market. For instance, the National Institute of Standards and Technology (NIST), an agency of the United States Department of Commerce, issued biomanufacturing initiative and stringent regulatory guidelines to ensure safe and effective manufacturing of low-cost, high-quality drugs globally. The objective of NIST biomanufacturing program is to support US biopharmaceutical industry delivery of high quality and low cost protein drugs around the world.

CMI table icon

Protein Engineering Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 1,936.7  Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 15.6% 2028 Value Projection: US$ 5,355.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Modified Enzymes, Insulin, Monoclonal Antibodies, Coagulation Factors (Blood Factors + Tissue Plasminogen), Vaccines, Growth Factors (Hormones + Cytokine), and Other Product Types
  • By Technology: Irrational Protein Design and Rational Protein Design
  • By End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CRO), and Academic Institutions)
Companies covered:

Codexis Inc., Abzena, Ltd., Enantis s.r.o, GenScript Biotech Corp., Waters Corporation, PerkinElmer, Inc., Bruker Corporation, Agilent Technologies, Bio-Rad Laboratories Inc., and Thermo Fisher Scientific Inc., among others

Growth Drivers:
  • Increase in adoption of protein drugs over non-protein drugs
  • Increase in prevalence of protein deficient diseases
Restraints & Challenges:
  • High production costs of therapeutic proteins
  • Dearth of skilled professionals

Global Protein Engineering Market Trends:

Growing adoption of monoclonal antibodies for the treatment of cancer and other autoimmune diseases is one of the most prevalent trend in the protein engineering market. High prevalence of chronic diseases, such as cancer, has significantly increased the use of monoclonal bodies. Thus, with the increase in incidence of chronic diseases, the use of protein engineering is also increasing, and this trend is expected to continue during the forecast period.

Moreover, the growth of the protein engineering market can also be attributed to the increasing focus on the development of therapeutic proteins. Protein drugs have potential applications as therapeutic agents since they have higher efficacy and lower toxicity as compared to chemical drugs. Some FDA approved peptide drugs are also available in the market, and the number of such drugs is expected to increase over the forecast period.

Global Protein Engineering Market Restraints:

High production costs of therapeutic proteins is expected to hamper the growth of the global protein engineering market. For instance, the development cost of therapeutic proteins is high, its computational cost resists some specialists to use this approach in the designing process. As a result, specialists use alternative methods for the development of therapeutic proteins.

Dearth of skilled professionals is expected to hinder growth of the global protein engineering market. For instance, despite many investments in the protein engineering segment, there is a shortage of skilled workforce in developed and developing countries. For instance, advanced protein engineering technologies require skilled technicians.

Figure 2. Global Protein Engineering Market Share (%), by Protein Type, 2021

Protein Engineering  | Coherent Market Insights

Global Protein Engineering Market Segmentation:

The global protein engineering market report is segmented into Product Type, Technology, End-User, and Geography.

Based on Product Type, the protein engineering market is segmented into Modified Enzymes, Insulin, Monoclonal Antibodies, Coagulation Factors (Blood Factors + Tissue Plasminogen), Vaccines, Growth Factors (Hormones + Cytokine), & Other Product Types. Of which, Insulin Segment is expected to dominate the protein engineering market over the forecast period and this is attributed to the increase in prevalence of diabetes. According to the WHO, around 422 million people worldwide have diabetes.

Monoclonal Antibodies Segment is also expected to witness significant growth in the near future and this is owing to the increase in adoption of monoclonal antibodies for the treatment of cancer and other autoimmune diseases. The increasing prevalence of autoimmune diseases has significantly increased the use of monoclonal bodies for the treatment of such diseases.

Based on Technology, the market is segmented into Irrational Protein Design and Rational Protein Design. Out of which, Rational Protein Design Segment is expected to dominate the market over the forecast period and this is attributed to the extensive usage of this technology in antibody and enzyme engineering. This technology holds substantial promise for optimizing the desired properties for commercial applications.

Based on End User, the global protein engineering market is segmented into Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CRO), and Academic Institutions. Of which, Pharmaceutical and Biotechnology Companies Segment is expected to dominate the market over the forecast period and this is attributed to the increasing focus on the development of new protein-based drugs. Protein-based drugs can be used to treat cancer, diabetes, and central nervous system diseases.

Contract Research Organizations Segment is also expected to witness significant growth in the near future and this is owing to the growing inclination of pharma and biotech companies to reduce overall expenditure along with utilization of benefits involved. It primarily includes cost advantages, enhanced productivity, increased efficiency of services, and higher focus on the core areas of development-all of which are critical to a company’s growth.

Global Protein Engineering Market: Key Developments

In January 2022, Amgen and Generate Biomedicines collaborated to discover or create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

In August 2019, Agilent Technologies acquired BioTek Instruments to expand its expertise in cell analysis and establish its position in the immuno-oncology and immunotherapy markets.

Global Protein Engineering Market: Key Companies Insights

The global protein engineering market is highly competitive. This is attributed to the increase in prevalence of chronic diseases and growing geriatric population, as a result, players in the market are focusing on launching novel drugs in the market.

Some of the key players in the global protein engineering market are Codexis Inc., Abzena, Ltd., Enantis s.r.o, GenScript Biotech Corp., Waters Corporation, PerkinElmer, Inc., Bruker Corporation, Agilent Technologies, Bio-Rad Laboratories Inc., and Thermo Fisher Scientific Inc., among others.

*Definition: Protein engineering holds the potential to transform metabolic drug landscape through the development of smart, stimulus-responsive drug systems. Protein therapeutics are a rapidly expanding segment of Food and Drug Administration (FDA) approved drugs that will improve clinical outcomes over the long run.  

Protein engineering is the process of developing useful and/or valuable proteins (protein drugs). Protein therapeutics are a rapidly expanding segment of FDA approved drugs that will improve clinical outcomes over the long run. The technology can be used to develop protein therapeutics (drugs) for the treatment of various chronic diseases and other autoimmune diseases. Protein engineering is a branch of biotechnology that includes genetic engineering, biotechnology, and biotechnology-related fields.

Market Dynamics:

Increase in prevalence of chronic diseases, increase in prevalence of protein deficient diseases, increase in adoption of protein drugs over non-protein drugs, rise in focus on the development of protein therapeutics, and rising government funding for protein engineering are major factors expected to drive growth of the global protein engineering market.

Market players are focusing on developing protein-drugs to treat various chronic diseases. For instance, in May 2021, Zydus Cadila announced the launched Trastuzumab Emtansine, the first Antibody Drug Conjugate biosimilar, Ujvira, to treat both early and advanced HER2 positive breast cancer. The rising burden of cancer cases among the population is increasing the demand for better treatment options, driving the market growth.

Key features of the study:

  • This report provides in-depth analysis of the global protein engineering market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global protein engineering market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Codexis Inc., Abzena, Ltd., Enantis s.r.o, GenScript Biotech Corp., Waters Corporation, PerkinElmer, Inc., Bruker Corporation, Agilent Technologies, Bio-Rad Laboratories Inc., and Thermo Fisher Scientific Inc., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global protein engineering market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global protein engineering market.

Detailed Segmentation:

  • Global Protein Engineering Market, By Product Type:
    • Modified Enzymes
    • Insulin
    • Monoclonal Antibodies
    • Coagulation Factors (Blood Factors + Tissue Plasminogen)
    • Vaccines
    • Growth Factors (Hormones + Cytokine)
    • Other Product Types
  • Global Protein Engineering Market, By Technology:
    • Irrational Protein Design
    • Rational Protein Design
  • Global Protein Engineering Market, By End User:
    • Pharmaceutical and Biotechnology Companies
    • Contract Research Organizations (CRO)
    • Academic Institutions
  • Global Protein Engineering Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Codexis Inc.
    • Abzena, Ltd.
    • Enantis s.r.o.
    • GenScript Biotech Corp.
    • Waters Corporation
    • PerkinElmer, Inc.
    • Bruker Corporation
    • Agilent Technologies
    • Bio-Rad Laboratories Inc.
    • Thermo Fisher Scientific Inc.

Frequently Asked Questions

The global protein engineering market size is estimated to be valued at US$ 2,238.5 Million in 2022 and is expected to exhibit a CAGR of 15.6% between 2022 and 2028.
Increase in adoption of protein drugs over non-protein drugs and rise in prevalence of protein deficient diseases is fueling the growth of the market.
Monoclonal Antibodies segment is the leading protein type segment in the market.
High production costs of therapeutic proteins and dearth of skilled professionals are major factors restraining growth of the market.
Major players operating in the market are Codexis Inc., Abzena, Ltd., Enantis s.r.o, GenScript Biotech Corp., Waters Corporation, PerkinElmer, Inc., Bruker Corporation, Agilent Technologies, Bio-Rad Laboratories Inc., and Thermo Fisher Scientific Inc., among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo